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patients, preoperative radiotherapy appears to be a good 
option for breast conserving therapy.  
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Purpose/Objective: There is a strong inverse association 
between the proliferation indices of early- and late-
responding normal tissues and their sensitivity to 
radiotherapy fraction size. The aim of this study is to test for 
association between Ki67 index and the fractionation 
sensitivity of breast cancer. The hypothesis is that tumours 
with high Ki67 indices are relatively insensitive to fraction 
size and over-represented in tumours relapsing after 
hypofractionated radiotherapy.  
Materials and Methods: Between 1986 and 2003, the START-
P and START-A trials each tested 2 test dose levels of a 13-
fraction regimen (3.0 vs 3.3 Gy & 3.0 vs 3.2 Gy fractions, 
respectively) in 5 weeks against 25 fractions of 2.0 Gy 
following primary surgery for early breast cancer. Primary 
tumour blocks of patients with local tumour relapse were 
collected for immunohistochemistry (IHC) for Ki67, HER2, ER, 
PR, CK5/6, EGFR, Geminin, Cyclin A, ATM, BRCA, PTEN and 
p53. A novel image-processing algorithm was developed to 
enable in silico alignment of serial tumor sections on a pixel-
level and subsequent automated Ki67 scoring. For the initial 
Ki67 assessment all relapsed patients in the test arms were 
grouped together.  
Results: From a total of 3646 patients entered into the 
START-P & -A trials, 261 local tumour relapses were recorded 
at a median follow up of 8.4 years (range 0.9-17.5) and 7.2 
years (range 0.7-11.9), respectively. Blocks from 213 patients 
were recovered, of which 181 were evaluable by IHC. There 
was no significant difference in proliferation between 
tumours relapsing after conventional and hypofractionated 
radiotherapy, with mean Ki67 scores of 7.63 (95%CI: 5.06-
11.5) and 5.33 (95CI%: 3.86-7.35), respectively. There was a 
positive correlation between Ki67 and Geminin scores 
(r=0.43, 95%CI 0.30-0.54, p<0.0001). The ongoing automated 
Ki67 scoring done in 41 patients so far has shown a high 
degree of correlation with manual scoring (r=0.76, 95%CI 
0.60-0.6, p<0.0001). Based on unsupervised hierarchical 
clustering analysisof biomarker expression (binarised data) 
patients were grouped mainly intoER/PR+, CK5/6 & EGFR+ 
and Ki67 high expressors, recapitulating known breastcancer 
subtypes. However, based on this 12-biomarker profile, a 
subgroup of patients enriched for recurrences in the different 
dose fractionation schedules cannot be identified. 
Conclusions: An association between proliferative indices 
and fractionation sensitivity in breast tumours has not been 
demonstrated in the 2 trials analysed together, and adjusted 
analyses of any imbalances in tumour characteristics between 
trials will be presented.  
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Radiotherapy is an essential part of cancer care. Successive 
studies have shown radiotherapy to be inexpensive and cost-
effective. These studies are difficult to undertake and may 
not be applicable in different countries because of variations 
in work practices, wages and capital costs. A population-
based model of radiotherapy demand and benefits could 
provide an estimate cost effectiveness if it was coupled to 
cost data. It could be updated simply by adding new cost or 
epidemiological data. 
We have developed a model of every indication for 
radiotherapy that has allowed us to estimate that 48% of 
cancer cases in a Australian require radiotherapy at least 
once (http://tinyurl.com/pwkua34). It is possible to adapt 
the model to other countries by substituting the relevant 
proportions of cancer types and even stages for that country. 
The model has been expanded to estimate the number of 
fractions per indication and thus an average of 18 fractions is 
needed per course. We have also estimated the survival and 
local control benefit of radiotherapy at 5 years by tumour 
type. Using Markov modelling it is possible to calculate the 
number of Life Years Gained and thus we can calculate a 
survival benefit per fraction. By costing fractions in different 
countries it will be possible to estimate the cost per life year 
gained.  
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Europe is characterized by its highly heterogeneous 
landscape with different cultures, traditions and languages. 
In the context of cancer care as well, large differences are 
observed in cancer incidence and survival, in economic 
aspects and available resources, in organization and funding 
of health care. Cost accounting and economic evaluation 
models should be developed that allow grasping this 
heterogeneity. 
The ESTRO Health Economics in Radiation Oncology (HERO) 
project wants to provide a blueprint of the European 
radiotherapy landscape from an economical perspective. The 
aim is to support the individual European countries and their 
national radiotherapy societies in developing and sustaining 
an optimal radiotherapy service, in line with evidence-based 
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recommendations, yet tuned to the national context and the 
economic specificities of the country. 
The first work-packages of the HERO project have 
objectivized a large variation within European countries in 
resource availability and in actual needs for radiotherapy 
provision, related to the national cancer incidence. It also 
showed a remarkable lack of guidance for radiotherapy 
planning, with national recommendations mostly duplicating 
the available recommendations from international 
organizations or projects, without any attempt to streamline 
them to the needs of the individual country. 
Due to the growing awareness of resource limitations and 
tightening budgets, the weighing of costs and outcomes as 
performed in economic evaluations have become an integral 
part of the health resource allocation processes in many 
countries. Whereas cost-effectiveness data are typically 
required prior to the introduction of new drugs, they 
gradually also become more frequently requested to support 
radiotherapy financing. In order to make valid 
recommendations, the economic evaluations should however 
mimic the actual clinical and economic situation of the 
specific country. Yet, cost-effectiveness data from one 
country are not necessarily representative for another. 
The next step within the HERO-project is to develop a costing 
model that provides accurate radiotherapy resource cost 
data, based on the available resources, the cancer 
epidemiology and the radiotherapy practice of individual 
European countries. Time-driven activity-based costing, a 
cost-accounting method specifically developed to capture 
product complexity and variability, is highly suitable for that 
purpose. A final step will be to evaluate how these cost data 
can be combined with effectiveness data – derived from 
international studies but applicable to a country-specific 
environment – in an adaptable economic evaluation model, 
relevant for individual countries in the heterogeneous 
European context. 
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Purpose/Objective: Despite significant improvement in 
locoregional control in the contemporary era of 
nasopharyngeal carcinoma (NPC) management, patients still 
suffer from a significant risk of distant metastasis (DM). 
Identifying those patients at risk of DM would aid in 
personalized treatment in the future. MicroRNAs (miRNAs) 
play many important roles in human cancers; hence, we 
proceeded to address the primary hypothesis that there is a 
miRNA expression signature capable of predicting DM for NPC 
patients. 
Materials and Methods: The expression of 734 miRNAs was 
measured in 125 (Training Set) and 121 (Validation Set) 
clinically annotated NPC diagnostic biopsy samples. 
Results: A 4-miRNA expression signature associated with risk 
of DM was generated by fitting a penalized Cox Proportion 
Hazard regression model to the Training data set (HR 8.25; 
p<0.001). This signature was subsequently tested in the 
Validation set, and maintained a significant relationship with 
DM (HR 3.2; p=0.01). In addition, multivariate analysis 
determined that this 4-miRNA signature was the strongest 
independent predictor when clinical factors were included. 
Finally, pathway enrichment analysis indicated that targets 
of the miRNAs comprising the final signature appear to be 
converging on cell cycle regulation. 
Conclusions: This 4-miRNA signature adds to the prognostic 
value of the current 'gold standard' of TNM staging. In-depth 
interrogation of these 4-miRNAs will provide important 
biological insights that could facilitate the discovery and 
development of novel molecularly targeted therapies to 
improve outcome for future NPC patients. 
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Purpose/Objective: Lysosome-associated membrane protein 
(LAMP)-3 is regulated by the unfolded protein response 
pathway. Our preclinical data suggest that LAMP3 plays an 
important role in autophagy induction during the response of 
breast cancer cells to various treatments and stress factors. 
We have shown that radiation therapy (RT), tamoxifen and 
hypoxia can induce LAMP3 and that high expression of LAMP3 
is associated with resistance to RT and tamoxifen in breast 
cancer cells. Moreover, patients with high levels of LAMP3 
mRNA had more locoregional recurrences. Here, we 
investigate the occurrence and clinical associations of a 
frequent non-synonymous single nucleotide polymorphism 
(SNP) in the LAMP3 gene (rs482912, Ile318Val) in 626 breast 
cancer patients. 
Materials and Methods: A custom TaqManÒ SNP Genotyping 
Assay targeted to our SNP of interest (rs482912) was used to 
assess its occurrence in breast cancer patients. We analysed 
the SNP's association with several clinical factors by Pearson 
Chi-square tests, and performed Kaplan-Meier survival and 
Cox regression analyses to investigate a relation with 
locoregional control. 
Results: In our cohort, the minor allele frequency for the 
LAMP3 rs482912SNP was 0.718, which is similar to the 
frequency in the European population. The SNP was not 
associated with menopausal status, type of operation, use of 
